Edition:
United States

GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

694JPY
1:00am EST
Change (% chg)

¥18 (+2.66%)
Prev Close
¥676
Open
¥669
Day's High
¥701
Day's Low
¥669
Volume
5,213,000
Avg. Vol
6,885,977
52-wk High
¥938
52-wk Low
¥216

Chart for

About

GNI Group Ltd. is a Japan-based company engaged in the drug discovery activities that utilize biotechnologies. The Company is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The... (more)
No analyst recommendations are available for .

Overall

Beta: 1.40
Market Cap(Mil.): ¥91,069.25
Shares Outstanding(Mil.): 134.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 215.97 17.86
EPS (TTM): -- -- --
ROI: -- -7.01 33.11
ROE: -- -27.69 17.05

BRIEF-GNI Group unit receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product

* Says unit Berkeley Advanced Biomaterials receives marketing approval for Bi-Ostetic Bioactive Glass Foam related product in U.S. from FDA

Oct 31 2017

BRIEF-GNI Group gets IND clearance by FDA for liver fibrosis treatment

* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis

Oct 09 2017

BRIEF- GNI Group unit says clearance of IND by FDA for F351 clinical trials in the treatment of liver fibrosis

* Says its wholly-owned subsidiary GNI USA, Inc had received U.S. FDA clearance on Sept. 29 (U.S. local time) for the Investigational New Drug application (IND) for F351 for U.S. clinical trials in the treatment of liver fibrosis

Oct 01 2017

Earnings vs. Estimates